nodes	percent_of_prediction	percent_of_DWPC	metapath
Adenosine—ADA—Pentostatin—hematologic cancer	0.0866	0.361	CbGbCtD
Adenosine—Pentostatin—hematologic cancer	0.0857	0.217	CrCtD
Adenosine—Clofarabine—hematologic cancer	0.0763	0.194	CrCtD
Adenosine—Nelarabine—hematologic cancer	0.0718	0.182	CrCtD
Adenosine—Fludarabine—hematologic cancer	0.056	0.142	CrCtD
Adenosine—Cytarabine—hematologic cancer	0.0529	0.134	CrCtD
Adenosine—Cladribine—hematologic cancer	0.0516	0.131	CrCtD
Adenosine—ADA—Nelarabine—hematologic cancer	0.0497	0.207	CbGbCtD
Adenosine—SLC28A3—Fludarabine—hematologic cancer	0.039	0.162	CbGbCtD
Adenosine—SLC28A3—Cladribine—hematologic cancer	0.0251	0.105	CbGbCtD
Adenosine—SLC28A3—Mercaptopurine—hematologic cancer	0.0234	0.0973	CbGbCtD
Adenosine—SLC28A3—Gemcitabine—hematologic cancer	0.0162	0.0675	CbGbCtD
Adenosine—Adenosine triphosphate—Nelarabine—hematologic cancer	0.00626	0.0238	CrCrCtD
Adenosine—Ribavirin—Clofarabine—hematologic cancer	0.00617	0.0234	CrCrCtD
Adenosine—Glucosamine—Cytarabine—hematologic cancer	0.00614	0.0233	CrCrCtD
Adenosine—Ribavirin—Nelarabine—hematologic cancer	0.0058	0.022	CrCrCtD
Adenosine—S-Adenosylmethionine—Clofarabine—hematologic cancer	0.00575	0.0218	CrCrCtD
Adenosine—Regadenoson—Clofarabine—hematologic cancer	0.00575	0.0218	CrCrCtD
Adenosine—S-Adenosylmethionine—Nelarabine—hematologic cancer	0.00541	0.0205	CrCrCtD
Adenosine—Regadenoson—Nelarabine—hematologic cancer	0.00541	0.0205	CrCrCtD
Adenosine—Clofarabine—Nelarabine—hematologic cancer	0.00541	0.0205	CrCrCtD
Adenosine—Fludarabine—Clofarabine—hematologic cancer	0.0054	0.0205	CrCrCtD
Adenosine—Vidarabine—Pentostatin—hematologic cancer	0.00513	0.0195	CrCrCtD
Adenosine—Cladribine—Pentostatin—hematologic cancer	0.00513	0.0195	CrCrCtD
Adenosine—Azacitidine—Pentostatin—hematologic cancer	0.00513	0.0195	CrCrCtD
Adenosine—Nelarabine—Clofarabine—hematologic cancer	0.00509	0.0193	CrCrCtD
Adenosine—Adenosine monophosphate—Clofarabine—hematologic cancer	0.00509	0.0193	CrCrCtD
Adenosine—Fludarabine—Nelarabine—hematologic cancer	0.00507	0.0193	CrCrCtD
Adenosine—Pentostatin—Cladribine—hematologic cancer	0.00489	0.0186	CrCrCtD
Adenosine—Adenosine triphosphate—Fludarabine—hematologic cancer	0.00489	0.0185	CrCrCtD
Adenosine—Decitabine—Pentostatin—hematologic cancer	0.00489	0.0185	CrCrCtD
Adenosine—Cytarabine—Clofarabine—hematologic cancer	0.00481	0.0183	CrCrCtD
Adenosine—Adenosine monophosphate—Nelarabine—hematologic cancer	0.00478	0.0181	CrCrCtD
Adenosine—Cladribine—Clofarabine—hematologic cancer	0.00457	0.0173	CrCrCtD
Adenosine—Azacitidine—Clofarabine—hematologic cancer	0.00457	0.0173	CrCrCtD
Adenosine—Vidarabine—Clofarabine—hematologic cancer	0.00457	0.0173	CrCrCtD
Adenosine—Ribavirin—Fludarabine—hematologic cancer	0.00453	0.0172	CrCrCtD
Adenosine—Cytarabine—Nelarabine—hematologic cancer	0.00453	0.0172	CrCrCtD
Adenosine—Decitabine—Clofarabine—hematologic cancer	0.00435	0.0165	CrCrCtD
Adenosine—Cladribine—Nelarabine—hematologic cancer	0.0043	0.0163	CrCrCtD
Adenosine—Vidarabine—Nelarabine—hematologic cancer	0.0043	0.0163	CrCrCtD
Adenosine—Azacitidine—Nelarabine—hematologic cancer	0.0043	0.0163	CrCrCtD
Adenosine—Ribavirin—Cytarabine—hematologic cancer	0.00428	0.0162	CrCrCtD
Adenosine—Regadenoson—Fludarabine—hematologic cancer	0.00422	0.016	CrCrCtD
Adenosine—S-Adenosylmethionine—Fludarabine—hematologic cancer	0.00422	0.016	CrCrCtD
Adenosine—Clofarabine—Fludarabine—hematologic cancer	0.00422	0.016	CrCrCtD
Adenosine—Decitabine—Nelarabine—hematologic cancer	0.00409	0.0155	CrCrCtD
Adenosine—Regadenoson—Cytarabine—hematologic cancer	0.00399	0.0151	CrCrCtD
Adenosine—S-Adenosylmethionine—Cytarabine—hematologic cancer	0.00399	0.0151	CrCrCtD
Adenosine—Clofarabine—Cytarabine—hematologic cancer	0.00399	0.0151	CrCrCtD
Adenosine—Regadenoson—Cladribine—hematologic cancer	0.00389	0.0148	CrCrCtD
Adenosine—Clofarabine—Cladribine—hematologic cancer	0.00389	0.0148	CrCrCtD
Adenosine—Fludarabine—Cytarabine—hematologic cancer	0.00374	0.0142	CrCrCtD
Adenosine—Adenosine monophosphate—Fludarabine—hematologic cancer	0.00373	0.0142	CrCrCtD
Adenosine—Nelarabine—Fludarabine—hematologic cancer	0.00373	0.0142	CrCrCtD
Adenosine—Fludarabine—Cladribine—hematologic cancer	0.00365	0.0138	CrCrCtD
Adenosine—Cytarabine—Fludarabine—hematologic cancer	0.00353	0.0134	CrCrCtD
Adenosine—Adenosine monophosphate—Cytarabine—hematologic cancer	0.00353	0.0134	CrCrCtD
Adenosine—Nelarabine—Cytarabine—hematologic cancer	0.00353	0.0134	CrCrCtD
Adenosine—Adenosine monophosphate—Cladribine—hematologic cancer	0.00344	0.013	CrCrCtD
Adenosine—Nelarabine—Cladribine—hematologic cancer	0.00344	0.013	CrCrCtD
Adenosine—Vidarabine—Fludarabine—hematologic cancer	0.00336	0.0127	CrCrCtD
Adenosine—Cladribine—Fludarabine—hematologic cancer	0.00336	0.0127	CrCrCtD
Adenosine—Azacitidine—Fludarabine—hematologic cancer	0.00336	0.0127	CrCrCtD
Adenosine—Cytarabine—Gemcitabine—hematologic cancer	0.00334	0.0127	CrCrCtD
Adenosine—Vidarabine—Cytarabine—hematologic cancer	0.00317	0.012	CrCrCtD
Adenosine—Azacitidine—Gemcitabine—hematologic cancer	0.00317	0.012	CrCrCtD
Adenosine—Azacitidine—Cytarabine—hematologic cancer	0.00317	0.012	CrCrCtD
Adenosine—Vidarabine—Cladribine—hematologic cancer	0.00309	0.0117	CrCrCtD
Adenosine—Azacitidine—Cladribine—hematologic cancer	0.00309	0.0117	CrCrCtD
Adenosine—Decitabine—Gemcitabine—hematologic cancer	0.00302	0.0115	CrCrCtD
Adenosine—Decitabine—Cytarabine—hematologic cancer	0.00302	0.0115	CrCrCtD
Adenosine—Decitabine—Cladribine—hematologic cancer	0.00294	0.0112	CrCrCtD
Adenosine—ADA—hematopoietic system—hematologic cancer	0.000769	0.0523	CbGeAlD
Adenosine—SLC28A3—bone marrow—hematologic cancer	0.000757	0.0514	CbGeAlD
Adenosine—ADORA2A—hematopoietic system—hematologic cancer	0.0007	0.0475	CbGeAlD
Adenosine—SLC28A3—lung—hematologic cancer	0.000686	0.0466	CbGeAlD
Adenosine—ADK—hematopoietic system—hematologic cancer	0.000629	0.0427	CbGeAlD
Adenosine—DPP4—hematopoietic system—hematologic cancer	0.000609	0.0414	CbGeAlD
Adenosine—ADORA1—hematopoietic system—hematologic cancer	0.000604	0.041	CbGeAlD
Adenosine—ADORA2B—blood—hematologic cancer	0.000557	0.0379	CbGeAlD
Adenosine—ADORA2A—gonad—hematologic cancer	0.000532	0.0361	CbGeAlD
Adenosine—ADA—blood—hematologic cancer	0.00051	0.0346	CbGeAlD
Adenosine—ADA—bone marrow—hematologic cancer	0.000493	0.0335	CbGeAlD
Adenosine—ADORA2B—lung—hematologic cancer	0.000489	0.0332	CbGeAlD
Adenosine—ADK—gonad—hematologic cancer	0.000478	0.0325	CbGeAlD
Adenosine—ADORA2A—blood—hematologic cancer	0.000464	0.0315	CbGeAlD
Adenosine—ADORA2B—testis—hematologic cancer	0.000461	0.0313	CbGeAlD
Adenosine—ADA—lung—hematologic cancer	0.000447	0.0304	CbGeAlD
Adenosine—ADA—testis—hematologic cancer	0.000422	0.0286	CbGeAlD
Adenosine—ADK—blood—hematologic cancer	0.000416	0.0283	CbGeAlD
Adenosine—DPP4—blood—hematologic cancer	0.000404	0.0274	CbGeAlD
Adenosine—ADK—bone marrow—hematologic cancer	0.000403	0.0274	CbGeAlD
Adenosine—DPP4—bone marrow—hematologic cancer	0.000391	0.0265	CbGeAlD
Adenosine—ADORA2A—testis—hematologic cancer	0.000384	0.0261	CbGeAlD
Adenosine—ADK—lung—hematologic cancer	0.000365	0.0248	CbGeAlD
Adenosine—DPP4—lung—hematologic cancer	0.000354	0.024	CbGeAlD
Adenosine—ADORA1—lung—hematologic cancer	0.000351	0.0238	CbGeAlD
Adenosine—ADK—testis—hematologic cancer	0.000344	0.0234	CbGeAlD
Adenosine—DPP4—testis—hematologic cancer	0.000334	0.0227	CbGeAlD
Adenosine—ADORA1—testis—hematologic cancer	0.000331	0.0225	CbGeAlD
Adenosine—ADA—lymph node—hematologic cancer	0.000306	0.0208	CbGeAlD
Adenosine—ADK—lymph node—hematologic cancer	0.00025	0.017	CbGeAlD
Adenosine—DPP4—lymph node—hematologic cancer	0.000242	0.0164	CbGeAlD
Adenosine—ADORA1—lymph node—hematologic cancer	0.00024	0.0163	CbGeAlD
Adenosine—Azacitidine—DNMT3A—hematologic cancer	0.000186	0.0934	CrCbGaD
Adenosine—Decitabine—DNMT3A—hematologic cancer	0.000182	0.0911	CrCbGaD
Adenosine—Azacitidine—CDA—hematologic cancer	0.000166	0.0832	CrCbGaD
Adenosine—Decitabine—DCK—hematologic cancer	0.000143	0.0715	CrCbGaD
Adenosine—Nelarabine—DCK—hematologic cancer	0.000137	0.0689	CrCbGaD
Adenosine—Clofarabine—DCK—hematologic cancer	0.000134	0.067	CrCbGaD
Adenosine—Fludarabine—DCK—hematologic cancer	0.000129	0.0649	CrCbGaD
Adenosine—Adenosine triphosphate—ASNS—hematologic cancer	9.78e-05	0.0491	CrCbGaD
Adenosine—Cytarabine—CDA—hematologic cancer	9.47e-05	0.0475	CrCbGaD
Adenosine—Glucosamine—IFNG—hematologic cancer	8.55e-05	0.0429	CrCbGaD
Adenosine—Adenosine monophosphate—CREB1—hematologic cancer	8.55e-05	0.0429	CrCbGaD
Adenosine—Cytarabine—DCK—hematologic cancer	8.34e-05	0.0418	CrCbGaD
Adenosine—Cladribine—DCK—hematologic cancer	7.67e-05	0.0385	CrCbGaD
Adenosine—Adenosine triphosphate—ABL2—hematologic cancer	7.41e-05	0.0372	CrCbGaD
Adenosine—Adenosine triphosphate—ALK—hematologic cancer	4.49e-05	0.0225	CrCbGaD
Adenosine—Glucosamine—TNF—hematologic cancer	3.58e-05	0.018	CrCbGaD
Adenosine—Adenosine triphosphate—AKT1—hematologic cancer	3.51e-05	0.0176	CrCbGaD
Adenosine—Adenosine monophosphate—SRC—hematologic cancer	3.46e-05	0.0173	CrCbGaD
Adenosine—Adenosine triphosphate—ABL1—hematologic cancer	3.31e-05	0.0166	CrCbGaD
Adenosine—Adenosine monophosphate—PDE4B—hematologic cancer	3.09e-05	0.0155	CrCbGaD
Adenosine—Clofarabine—ABCG2—hematologic cancer	3.01e-05	0.0151	CrCbGaD
Adenosine—Cytarabine—SLC22A1—hematologic cancer	2.69e-05	0.0135	CrCbGaD
Adenosine—Cladribine—SLC22A1—hematologic cancer	2.48e-05	0.0124	CrCbGaD
Adenosine—Cladribine—ABCG2—hematologic cancer	1.73e-05	0.00868	CrCbGaD
Adenosine—Dermatitis—Thalidomide—hematologic cancer	1.3e-05	0.000241	CcSEcCtD
Adenosine—Dizziness—Alitretinoin—hematologic cancer	1.3e-05	0.000241	CcSEcCtD
Adenosine—Headache—Thalidomide—hematologic cancer	1.3e-05	0.00024	CcSEcCtD
Adenosine—Pain—Prednisolone—hematologic cancer	1.3e-05	0.00024	CcSEcCtD
Adenosine—Sweating—Epirubicin—hematologic cancer	1.3e-05	0.00024	CcSEcCtD
Adenosine—Pollakiuria—Doxorubicin—hematologic cancer	1.3e-05	0.00024	CcSEcCtD
Adenosine—Asthenia—Gemcitabine—hematologic cancer	1.29e-05	0.000239	CcSEcCtD
Adenosine—Dizziness—Ifosfamide—hematologic cancer	1.29e-05	0.000238	CcSEcCtD
Adenosine—Vision blurred—Prednisone—hematologic cancer	1.27e-05	0.000236	CcSEcCtD
Adenosine—Nausea—Thiotepa—hematologic cancer	1.27e-05	0.000235	CcSEcCtD
Adenosine—Musculoskeletal discomfort—Triamcinolone—hematologic cancer	1.27e-05	0.000235	CcSEcCtD
Adenosine—Anaphylactic shock—Dexamethasone—hematologic cancer	1.27e-05	0.000234	CcSEcCtD
Adenosine—Anaphylactic shock—Betamethasone—hematologic cancer	1.27e-05	0.000234	CcSEcCtD
Adenosine—Vomiting—Carmustine—hematologic cancer	1.26e-05	0.000234	CcSEcCtD
Adenosine—Dizziness—Vincristine—hematologic cancer	1.26e-05	0.000232	CcSEcCtD
Adenosine—Rash—Carmustine—hematologic cancer	1.25e-05	0.000232	CcSEcCtD
Adenosine—Dermatitis—Carmustine—hematologic cancer	1.25e-05	0.000232	CcSEcCtD
Adenosine—Vomiting—Alitretinoin—hematologic cancer	1.25e-05	0.000232	CcSEcCtD
Adenosine—Paraesthesia—Triamcinolone—hematologic cancer	1.25e-05	0.000232	CcSEcCtD
Adenosine—Drowsiness—Doxorubicin—hematologic cancer	1.25e-05	0.000232	CcSEcCtD
Adenosine—Headache—Carmustine—hematologic cancer	1.25e-05	0.000231	CcSEcCtD
Adenosine—Shock—Betamethasone—hematologic cancer	1.24e-05	0.000231	CcSEcCtD
Adenosine—Shock—Dexamethasone—hematologic cancer	1.24e-05	0.000231	CcSEcCtD
Adenosine—Dyspnoea—Triamcinolone—hematologic cancer	1.24e-05	0.00023	CcSEcCtD
Adenosine—Rash—Alitretinoin—hematologic cancer	1.24e-05	0.00023	CcSEcCtD
Adenosine—Agitation—Prednisone—hematologic cancer	1.24e-05	0.00023	CcSEcCtD
Adenosine—Dermatitis—Alitretinoin—hematologic cancer	1.24e-05	0.00023	CcSEcCtD
Adenosine—Vomiting—Ifosfamide—hematologic cancer	1.24e-05	0.000229	CcSEcCtD
Adenosine—Hypersensitivity—Cisplatin—hematologic cancer	1.24e-05	0.000229	CcSEcCtD
Adenosine—Tachycardia—Dexamethasone—hematologic cancer	1.23e-05	0.000229	CcSEcCtD
Adenosine—Tachycardia—Betamethasone—hematologic cancer	1.23e-05	0.000229	CcSEcCtD
Adenosine—Bradycardia—Epirubicin—hematologic cancer	1.23e-05	0.000229	CcSEcCtD
Adenosine—Headache—Alitretinoin—hematologic cancer	1.23e-05	0.000228	CcSEcCtD
Adenosine—Angioedema—Prednisone—hematologic cancer	1.23e-05	0.000228	CcSEcCtD
Adenosine—Nausea—Thalidomide—hematologic cancer	1.23e-05	0.000228	CcSEcCtD
Adenosine—Rash—Ifosfamide—hematologic cancer	1.23e-05	0.000227	CcSEcCtD
Adenosine—Dermatitis—Ifosfamide—hematologic cancer	1.23e-05	0.000227	CcSEcCtD
Adenosine—Hyperhidrosis—Betamethasone—hematologic cancer	1.22e-05	0.000227	CcSEcCtD
Adenosine—Hyperhidrosis—Dexamethasone—hematologic cancer	1.22e-05	0.000227	CcSEcCtD
Adenosine—Dizziness—Irinotecan—hematologic cancer	1.22e-05	0.000226	CcSEcCtD
Adenosine—Urticaria—Etoposide—hematologic cancer	1.22e-05	0.000226	CcSEcCtD
Adenosine—Syncope—Prednisone—hematologic cancer	1.21e-05	0.000224	CcSEcCtD
Adenosine—Tinnitus—Methotrexate—hematologic cancer	1.21e-05	0.000224	CcSEcCtD
Adenosine—Hypoaesthesia—Epirubicin—hematologic cancer	1.21e-05	0.000224	CcSEcCtD
Adenosine—Vomiting—Vincristine—hematologic cancer	1.21e-05	0.000223	CcSEcCtD
Adenosine—Urticaria—Prednisolone—hematologic cancer	1.2e-05	0.000223	CcSEcCtD
Adenosine—Asthenia—Cisplatin—hematologic cancer	1.2e-05	0.000223	CcSEcCtD
Adenosine—Cardiac disorder—Methotrexate—hematologic cancer	1.2e-05	0.000223	CcSEcCtD
Adenosine—Sweating—Doxorubicin—hematologic cancer	1.2e-05	0.000222	CcSEcCtD
Adenosine—Rash—Vincristine—hematologic cancer	1.2e-05	0.000222	CcSEcCtD
Adenosine—Dermatitis—Vincristine—hematologic cancer	1.2e-05	0.000221	CcSEcCtD
Adenosine—Pain—Triamcinolone—hematologic cancer	1.19e-05	0.000221	CcSEcCtD
Adenosine—Headache—Vincristine—hematologic cancer	1.19e-05	0.00022	CcSEcCtD
Adenosine—Loss of consciousness—Prednisone—hematologic cancer	1.19e-05	0.00022	CcSEcCtD
Adenosine—Hypotension—Betamethasone—hematologic cancer	1.18e-05	0.000219	CcSEcCtD
Adenosine—Hypotension—Dexamethasone—hematologic cancer	1.18e-05	0.000219	CcSEcCtD
Adenosine—Nausea—Carmustine—hematologic cancer	1.18e-05	0.000219	CcSEcCtD
Adenosine—Vomiting—Mitoxantrone—hematologic cancer	1.18e-05	0.000218	CcSEcCtD
Adenosine—Vomiting—Irinotecan—hematologic cancer	1.18e-05	0.000218	CcSEcCtD
Adenosine—Nausea—Alitretinoin—hematologic cancer	1.17e-05	0.000217	CcSEcCtD
Adenosine—Convulsion—Prednisone—hematologic cancer	1.17e-05	0.000217	CcSEcCtD
Adenosine—Mediastinal disorder—Methotrexate—hematologic cancer	1.17e-05	0.000216	CcSEcCtD
Adenosine—Hypertension—Prednisone—hematologic cancer	1.17e-05	0.000216	CcSEcCtD
Adenosine—Rash—Irinotecan—hematologic cancer	1.17e-05	0.000216	CcSEcCtD
Adenosine—Rash—Mitoxantrone—hematologic cancer	1.17e-05	0.000216	CcSEcCtD
Adenosine—Dermatitis—Mitoxantrone—hematologic cancer	1.16e-05	0.000216	CcSEcCtD
Adenosine—Dermatitis—Irinotecan—hematologic cancer	1.16e-05	0.000216	CcSEcCtD
Adenosine—Headache—Irinotecan—hematologic cancer	1.16e-05	0.000214	CcSEcCtD
Adenosine—Headache—Mitoxantrone—hematologic cancer	1.16e-05	0.000214	CcSEcCtD
Adenosine—Nausea—Ifosfamide—hematologic cancer	1.16e-05	0.000214	CcSEcCtD
Adenosine—Musculoskeletal discomfort—Betamethasone—hematologic cancer	1.15e-05	0.000213	CcSEcCtD
Adenosine—Musculoskeletal discomfort—Dexamethasone—hematologic cancer	1.15e-05	0.000213	CcSEcCtD
Adenosine—Anxiety—Prednisone—hematologic cancer	1.15e-05	0.000212	CcSEcCtD
Adenosine—Vomiting—Gemcitabine—hematologic cancer	1.14e-05	0.000212	CcSEcCtD
Adenosine—Bradycardia—Doxorubicin—hematologic cancer	1.14e-05	0.000212	CcSEcCtD
Adenosine—Paraesthesia—Betamethasone—hematologic cancer	1.14e-05	0.00021	CcSEcCtD
Adenosine—Paraesthesia—Dexamethasone—hematologic cancer	1.14e-05	0.00021	CcSEcCtD
Adenosine—Discomfort—Prednisone—hematologic cancer	1.14e-05	0.00021	CcSEcCtD
Adenosine—Rash—Gemcitabine—hematologic cancer	1.14e-05	0.00021	CcSEcCtD
Adenosine—Dermatitis—Gemcitabine—hematologic cancer	1.13e-05	0.00021	CcSEcCtD
Adenosine—Hypersensitivity—Etoposide—hematologic cancer	1.13e-05	0.00021	CcSEcCtD
Adenosine—Tinnitus—Epirubicin—hematologic cancer	1.13e-05	0.000209	CcSEcCtD
Adenosine—Headache—Gemcitabine—hematologic cancer	1.13e-05	0.000209	CcSEcCtD
Adenosine—Nausea—Vincristine—hematologic cancer	1.13e-05	0.000209	CcSEcCtD
Adenosine—Flushing—Epirubicin—hematologic cancer	1.13e-05	0.000208	CcSEcCtD
Adenosine—Cardiac disorder—Epirubicin—hematologic cancer	1.13e-05	0.000208	CcSEcCtD
Adenosine—Hypersensitivity—Prednisolone—hematologic cancer	1.12e-05	0.000207	CcSEcCtD
Adenosine—Hypoaesthesia—Doxorubicin—hematologic cancer	1.12e-05	0.000207	CcSEcCtD
Adenosine—Urticaria—Triamcinolone—hematologic cancer	1.11e-05	0.000205	CcSEcCtD
Adenosine—Dysgeusia—Methotrexate—hematologic cancer	1.11e-05	0.000205	CcSEcCtD
Adenosine—Asthenia—Etoposide—hematologic cancer	1.1e-05	0.000204	CcSEcCtD
Adenosine—Anaphylactic shock—Prednisone—hematologic cancer	1.1e-05	0.000204	CcSEcCtD
Adenosine—Nausea—Mitoxantrone—hematologic cancer	1.1e-05	0.000203	CcSEcCtD
Adenosine—Nausea—Irinotecan—hematologic cancer	1.1e-05	0.000203	CcSEcCtD
Adenosine—Mediastinal disorder—Epirubicin—hematologic cancer	1.09e-05	0.000202	CcSEcCtD
Adenosine—Back pain—Methotrexate—hematologic cancer	1.09e-05	0.000202	CcSEcCtD
Adenosine—Shock—Prednisone—hematologic cancer	1.08e-05	0.000201	CcSEcCtD
Adenosine—Arrhythmia—Epirubicin—hematologic cancer	1.08e-05	0.000201	CcSEcCtD
Adenosine—Pain—Dexamethasone—hematologic cancer	1.08e-05	0.0002	CcSEcCtD
Adenosine—Pain—Betamethasone—hematologic cancer	1.08e-05	0.0002	CcSEcCtD
Adenosine—Tachycardia—Prednisone—hematologic cancer	1.08e-05	0.000199	CcSEcCtD
Adenosine—Nausea—Gemcitabine—hematologic cancer	1.07e-05	0.000198	CcSEcCtD
Adenosine—Vomiting—Cisplatin—hematologic cancer	1.07e-05	0.000198	CcSEcCtD
Adenosine—Hyperhidrosis—Prednisone—hematologic cancer	1.07e-05	0.000197	CcSEcCtD
Adenosine—Vision blurred—Methotrexate—hematologic cancer	1.06e-05	0.000197	CcSEcCtD
Adenosine—Rash—Cisplatin—hematologic cancer	1.06e-05	0.000196	CcSEcCtD
Adenosine—Dermatitis—Cisplatin—hematologic cancer	1.06e-05	0.000196	CcSEcCtD
Adenosine—Tinnitus—Doxorubicin—hematologic cancer	1.05e-05	0.000194	CcSEcCtD
Adenosine—Flushing—Doxorubicin—hematologic cancer	1.04e-05	0.000193	CcSEcCtD
Adenosine—Cardiac disorder—Doxorubicin—hematologic cancer	1.04e-05	0.000193	CcSEcCtD
Adenosine—Tension—Epirubicin—hematologic cancer	1.04e-05	0.000192	CcSEcCtD
Adenosine—Dysgeusia—Epirubicin—hematologic cancer	1.03e-05	0.000191	CcSEcCtD
Adenosine—Hypersensitivity—Triamcinolone—hematologic cancer	1.03e-05	0.00019	CcSEcCtD
Adenosine—Nervousness—Epirubicin—hematologic cancer	1.03e-05	0.00019	CcSEcCtD
Adenosine—Back pain—Epirubicin—hematologic cancer	1.02e-05	0.000189	CcSEcCtD
Adenosine—Dizziness—Etoposide—hematologic cancer	1.02e-05	0.000188	CcSEcCtD
Adenosine—Mediastinal disorder—Doxorubicin—hematologic cancer	1.01e-05	0.000187	CcSEcCtD
Adenosine—Urticaria—Dexamethasone—hematologic cancer	1.01e-05	0.000186	CcSEcCtD
Adenosine—Urticaria—Betamethasone—hematologic cancer	1.01e-05	0.000186	CcSEcCtD
Adenosine—Musculoskeletal discomfort—Prednisone—hematologic cancer	1e-05	0.000186	CcSEcCtD
Adenosine—Dizziness—Prednisolone—hematologic cancer	1e-05	0.000186	CcSEcCtD
Adenosine—Arrhythmia—Doxorubicin—hematologic cancer	1e-05	0.000186	CcSEcCtD
Adenosine—Asthenia—Triamcinolone—hematologic cancer	1e-05	0.000185	CcSEcCtD
Adenosine—Nausea—Cisplatin—hematologic cancer	9.97e-06	0.000185	CcSEcCtD
Adenosine—Vision blurred—Epirubicin—hematologic cancer	9.95e-06	0.000184	CcSEcCtD
Adenosine—Paraesthesia—Prednisone—hematologic cancer	9.89e-06	0.000183	CcSEcCtD
Adenosine—Cough—Methotrexate—hematologic cancer	9.85e-06	0.000182	CcSEcCtD
Adenosine—Convulsion—Methotrexate—hematologic cancer	9.78e-06	0.000181	CcSEcCtD
Adenosine—Vomiting—Etoposide—hematologic cancer	9.78e-06	0.000181	CcSEcCtD
Adenosine—Agitation—Epirubicin—hematologic cancer	9.7e-06	0.00018	CcSEcCtD
Adenosine—Rash—Etoposide—hematologic cancer	9.69e-06	0.00018	CcSEcCtD
Adenosine—Dermatitis—Etoposide—hematologic cancer	9.69e-06	0.000179	CcSEcCtD
Adenosine—Headache—Etoposide—hematologic cancer	9.63e-06	0.000178	CcSEcCtD
Adenosine—Chest pain—Methotrexate—hematologic cancer	9.61e-06	0.000178	CcSEcCtD
Adenosine—Tension—Doxorubicin—hematologic cancer	9.59e-06	0.000178	CcSEcCtD
Adenosine—Dysgeusia—Doxorubicin—hematologic cancer	9.57e-06	0.000177	CcSEcCtD
Adenosine—Rash—Prednisolone—hematologic cancer	9.56e-06	0.000177	CcSEcCtD
Adenosine—Dermatitis—Prednisolone—hematologic cancer	9.55e-06	0.000177	CcSEcCtD
Adenosine—Headache—Prednisolone—hematologic cancer	9.5e-06	0.000176	CcSEcCtD
Adenosine—Discomfort—Methotrexate—hematologic cancer	9.49e-06	0.000176	CcSEcCtD
Adenosine—Nervousness—Doxorubicin—hematologic cancer	9.49e-06	0.000176	CcSEcCtD
Adenosine—Syncope—Epirubicin—hematologic cancer	9.47e-06	0.000175	CcSEcCtD
Adenosine—Back pain—Doxorubicin—hematologic cancer	9.45e-06	0.000175	CcSEcCtD
Adenosine—Palpitations—Epirubicin—hematologic cancer	9.33e-06	0.000173	CcSEcCtD
Adenosine—Loss of consciousness—Epirubicin—hematologic cancer	9.28e-06	0.000172	CcSEcCtD
Adenosine—Dizziness—Triamcinolone—hematologic cancer	9.22e-06	0.000171	CcSEcCtD
Adenosine—Cough—Epirubicin—hematologic cancer	9.21e-06	0.000171	CcSEcCtD
Adenosine—Anaphylactic shock—Methotrexate—hematologic cancer	9.21e-06	0.000171	CcSEcCtD
Adenosine—Vision blurred—Doxorubicin—hematologic cancer	9.21e-06	0.000171	CcSEcCtD
Adenosine—Convulsion—Epirubicin—hematologic cancer	9.15e-06	0.000169	CcSEcCtD
Adenosine—Nausea—Etoposide—hematologic cancer	9.13e-06	0.000169	CcSEcCtD
Adenosine—Hypertension—Epirubicin—hematologic cancer	9.12e-06	0.000169	CcSEcCtD
Adenosine—Asthenia—Dexamethasone—hematologic cancer	9.08e-06	0.000168	CcSEcCtD
Adenosine—Asthenia—Betamethasone—hematologic cancer	9.08e-06	0.000168	CcSEcCtD
Adenosine—Nausea—Prednisolone—hematologic cancer	9.01e-06	0.000167	CcSEcCtD
Adenosine—Chest pain—Epirubicin—hematologic cancer	8.99e-06	0.000166	CcSEcCtD
Adenosine—Agitation—Doxorubicin—hematologic cancer	8.98e-06	0.000166	CcSEcCtD
Adenosine—Anxiety—Epirubicin—hematologic cancer	8.96e-06	0.000166	CcSEcCtD
Adenosine—Hyperhidrosis—Methotrexate—hematologic cancer	8.9e-06	0.000165	CcSEcCtD
Adenosine—Discomfort—Epirubicin—hematologic cancer	8.88e-06	0.000164	CcSEcCtD
Adenosine—Vomiting—Triamcinolone—hematologic cancer	8.87e-06	0.000164	CcSEcCtD
Adenosine—Rash—Triamcinolone—hematologic cancer	8.79e-06	0.000163	CcSEcCtD
Adenosine—Dry mouth—Epirubicin—hematologic cancer	8.79e-06	0.000163	CcSEcCtD
Adenosine—Dermatitis—Triamcinolone—hematologic cancer	8.78e-06	0.000163	CcSEcCtD
Adenosine—Syncope—Doxorubicin—hematologic cancer	8.76e-06	0.000162	CcSEcCtD
Adenosine—Urticaria—Prednisone—hematologic cancer	8.75e-06	0.000162	CcSEcCtD
Adenosine—Headache—Triamcinolone—hematologic cancer	8.74e-06	0.000162	CcSEcCtD
Adenosine—Palpitations—Doxorubicin—hematologic cancer	8.63e-06	0.00016	CcSEcCtD
Adenosine—Anaphylactic shock—Epirubicin—hematologic cancer	8.62e-06	0.00016	CcSEcCtD
Adenosine—Hypotension—Methotrexate—hematologic cancer	8.61e-06	0.000159	CcSEcCtD
Adenosine—Loss of consciousness—Doxorubicin—hematologic cancer	8.59e-06	0.000159	CcSEcCtD
Adenosine—Cough—Doxorubicin—hematologic cancer	8.53e-06	0.000158	CcSEcCtD
Adenosine—Shock—Epirubicin—hematologic cancer	8.48e-06	0.000157	CcSEcCtD
Adenosine—Convulsion—Doxorubicin—hematologic cancer	8.47e-06	0.000157	CcSEcCtD
Adenosine—Hypertension—Doxorubicin—hematologic cancer	8.44e-06	0.000156	CcSEcCtD
Adenosine—Tachycardia—Epirubicin—hematologic cancer	8.41e-06	0.000156	CcSEcCtD
Adenosine—Musculoskeletal discomfort—Methotrexate—hematologic cancer	8.39e-06	0.000155	CcSEcCtD
Adenosine—Dizziness—Dexamethasone—hematologic cancer	8.37e-06	0.000155	CcSEcCtD
Adenosine—Dizziness—Betamethasone—hematologic cancer	8.37e-06	0.000155	CcSEcCtD
Adenosine—Hyperhidrosis—Epirubicin—hematologic cancer	8.33e-06	0.000154	CcSEcCtD
Adenosine—Chest pain—Doxorubicin—hematologic cancer	8.32e-06	0.000154	CcSEcCtD
Adenosine—Anxiety—Doxorubicin—hematologic cancer	8.29e-06	0.000154	CcSEcCtD
Adenosine—Nausea—Triamcinolone—hematologic cancer	8.28e-06	0.000153	CcSEcCtD
Adenosine—Paraesthesia—Methotrexate—hematologic cancer	8.27e-06	0.000153	CcSEcCtD
Adenosine—Discomfort—Doxorubicin—hematologic cancer	8.22e-06	0.000152	CcSEcCtD
Adenosine—Dyspnoea—Methotrexate—hematologic cancer	8.21e-06	0.000152	CcSEcCtD
Adenosine—Somnolence—Methotrexate—hematologic cancer	8.19e-06	0.000152	CcSEcCtD
Adenosine—Dry mouth—Doxorubicin—hematologic cancer	8.14e-06	0.000151	CcSEcCtD
Adenosine—Hypersensitivity—Prednisone—hematologic cancer	8.12e-06	0.00015	CcSEcCtD
Adenosine—Hypotension—Epirubicin—hematologic cancer	8.05e-06	0.000149	CcSEcCtD
Adenosine—Vomiting—Betamethasone—hematologic cancer	8.05e-06	0.000149	CcSEcCtD
Adenosine—Vomiting—Dexamethasone—hematologic cancer	8.05e-06	0.000149	CcSEcCtD
Adenosine—Rash—Dexamethasone—hematologic cancer	7.98e-06	0.000148	CcSEcCtD
Adenosine—Rash—Betamethasone—hematologic cancer	7.98e-06	0.000148	CcSEcCtD
Adenosine—Anaphylactic shock—Doxorubicin—hematologic cancer	7.97e-06	0.000148	CcSEcCtD
Adenosine—Dermatitis—Betamethasone—hematologic cancer	7.97e-06	0.000148	CcSEcCtD
Adenosine—Dermatitis—Dexamethasone—hematologic cancer	7.97e-06	0.000148	CcSEcCtD
Adenosine—Headache—Betamethasone—hematologic cancer	7.93e-06	0.000147	CcSEcCtD
Adenosine—Headache—Dexamethasone—hematologic cancer	7.93e-06	0.000147	CcSEcCtD
Adenosine—Asthenia—Prednisone—hematologic cancer	7.91e-06	0.000146	CcSEcCtD
Adenosine—Pain—Methotrexate—hematologic cancer	7.88e-06	0.000146	CcSEcCtD
Adenosine—Musculoskeletal discomfort—Epirubicin—hematologic cancer	7.85e-06	0.000145	CcSEcCtD
Adenosine—Shock—Doxorubicin—hematologic cancer	7.85e-06	0.000145	CcSEcCtD
Adenosine—Tachycardia—Doxorubicin—hematologic cancer	7.78e-06	0.000144	CcSEcCtD
Adenosine—Paraesthesia—Epirubicin—hematologic cancer	7.74e-06	0.000143	CcSEcCtD
Adenosine—Hyperhidrosis—Doxorubicin—hematologic cancer	7.71e-06	0.000143	CcSEcCtD
Adenosine—Dyspnoea—Epirubicin—hematologic cancer	7.68e-06	0.000142	CcSEcCtD
Adenosine—Somnolence—Epirubicin—hematologic cancer	7.66e-06	0.000142	CcSEcCtD
Adenosine—Nausea—Betamethasone—hematologic cancer	7.52e-06	0.000139	CcSEcCtD
Adenosine—Nausea—Dexamethasone—hematologic cancer	7.52e-06	0.000139	CcSEcCtD
Adenosine—Hypotension—Doxorubicin—hematologic cancer	7.45e-06	0.000138	CcSEcCtD
Adenosine—Pain—Epirubicin—hematologic cancer	7.37e-06	0.000136	CcSEcCtD
Adenosine—Urticaria—Methotrexate—hematologic cancer	7.32e-06	0.000135	CcSEcCtD
Adenosine—Dizziness—Prednisone—hematologic cancer	7.29e-06	0.000135	CcSEcCtD
Adenosine—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	7.27e-06	0.000135	CcSEcCtD
Adenosine—Paraesthesia—Doxorubicin—hematologic cancer	7.16e-06	0.000133	CcSEcCtD
Adenosine—Dyspnoea—Doxorubicin—hematologic cancer	7.11e-06	0.000132	CcSEcCtD
Adenosine—Somnolence—Doxorubicin—hematologic cancer	7.09e-06	0.000131	CcSEcCtD
Adenosine—Vomiting—Prednisone—hematologic cancer	7.01e-06	0.00013	CcSEcCtD
Adenosine—Rash—Prednisone—hematologic cancer	6.95e-06	0.000129	CcSEcCtD
Adenosine—Dermatitis—Prednisone—hematologic cancer	6.94e-06	0.000129	CcSEcCtD
Adenosine—Headache—Prednisone—hematologic cancer	6.9e-06	0.000128	CcSEcCtD
Adenosine—Urticaria—Epirubicin—hematologic cancer	6.85e-06	0.000127	CcSEcCtD
Adenosine—Pain—Doxorubicin—hematologic cancer	6.82e-06	0.000126	CcSEcCtD
Adenosine—Hypersensitivity—Methotrexate—hematologic cancer	6.79e-06	0.000126	CcSEcCtD
Adenosine—Asthenia—Methotrexate—hematologic cancer	6.61e-06	0.000122	CcSEcCtD
Adenosine—Nausea—Prednisone—hematologic cancer	6.55e-06	0.000121	CcSEcCtD
Adenosine—Hypersensitivity—Epirubicin—hematologic cancer	6.35e-06	0.000118	CcSEcCtD
Adenosine—Urticaria—Doxorubicin—hematologic cancer	6.34e-06	0.000117	CcSEcCtD
Adenosine—Asthenia—Epirubicin—hematologic cancer	6.18e-06	0.000115	CcSEcCtD
Adenosine—Adenosine triphosphate—ABCB1—hematologic cancer	6.12e-06	0.00307	CrCbGaD
Adenosine—Dizziness—Methotrexate—hematologic cancer	6.09e-06	0.000113	CcSEcCtD
Adenosine—Hypersensitivity—Doxorubicin—hematologic cancer	5.88e-06	0.000109	CcSEcCtD
Adenosine—Vomiting—Methotrexate—hematologic cancer	5.86e-06	0.000108	CcSEcCtD
Adenosine—Rash—Methotrexate—hematologic cancer	5.81e-06	0.000108	CcSEcCtD
Adenosine—Dermatitis—Methotrexate—hematologic cancer	5.8e-06	0.000107	CcSEcCtD
Adenosine—Headache—Methotrexate—hematologic cancer	5.77e-06	0.000107	CcSEcCtD
Adenosine—Asthenia—Doxorubicin—hematologic cancer	5.72e-06	0.000106	CcSEcCtD
Adenosine—Dizziness—Epirubicin—hematologic cancer	5.7e-06	0.000106	CcSEcCtD
Adenosine—Vomiting—Epirubicin—hematologic cancer	5.48e-06	0.000101	CcSEcCtD
Adenosine—Nausea—Methotrexate—hematologic cancer	5.47e-06	0.000101	CcSEcCtD
Adenosine—Rash—Epirubicin—hematologic cancer	5.43e-06	0.000101	CcSEcCtD
Adenosine—Dermatitis—Epirubicin—hematologic cancer	5.43e-06	0.000101	CcSEcCtD
Adenosine—Headache—Epirubicin—hematologic cancer	5.4e-06	0.0001	CcSEcCtD
Adenosine—Dizziness—Doxorubicin—hematologic cancer	5.27e-06	9.76e-05	CcSEcCtD
Adenosine—Nausea—Epirubicin—hematologic cancer	5.12e-06	9.48e-05	CcSEcCtD
Adenosine—Vomiting—Doxorubicin—hematologic cancer	5.07e-06	9.39e-05	CcSEcCtD
Adenosine—Rash—Doxorubicin—hematologic cancer	5.03e-06	9.31e-05	CcSEcCtD
Adenosine—Dermatitis—Doxorubicin—hematologic cancer	5.02e-06	9.3e-05	CcSEcCtD
Adenosine—Headache—Doxorubicin—hematologic cancer	5e-06	9.25e-05	CcSEcCtD
Adenosine—Nausea—Doxorubicin—hematologic cancer	4.74e-06	8.77e-05	CcSEcCtD
Adenosine—ADORA2A—GPCR downstream signaling—PIK3CG—hematologic cancer	3.2e-06	0.000102	CbGpPWpGaD
Adenosine—ADORA1—Signaling Pathways—STAT5A—hematologic cancer	3.19e-06	0.000101	CbGpPWpGaD
Adenosine—ADORA1—GPCR downstream signaling—PIK3CB—hematologic cancer	3.18e-06	0.000101	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—PARP1—hematologic cancer	3.16e-06	0.0001	CbGpPWpGaD
Adenosine—ADORA1—Signaling Pathways—CDKN2B—hematologic cancer	3.16e-06	0.0001	CbGpPWpGaD
Adenosine—ADA—Metabolism—PIK3CD—hematologic cancer	3.15e-06	9.97e-05	CbGpPWpGaD
Adenosine—ADORA2B—Signaling Pathways—IL2RA—hematologic cancer	3.14e-06	9.96e-05	CbGpPWpGaD
Adenosine—ADORA1—Signaling by GPCR—PIK3R1—hematologic cancer	3.13e-06	9.91e-05	CbGpPWpGaD
Adenosine—ADORA2B—Signaling by GPCR—IL2—hematologic cancer	3.12e-06	9.88e-05	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—FBXW7—hematologic cancer	3.11e-06	9.87e-05	CbGpPWpGaD
Adenosine—ADORA2B—Signaling Pathways—TERT—hematologic cancer	3.11e-06	9.85e-05	CbGpPWpGaD
Adenosine—ADA—Metabolism—ALB—hematologic cancer	3.11e-06	9.84e-05	CbGpPWpGaD
Adenosine—ADORA1—Signaling Pathways—CD86—hematologic cancer	3.06e-06	9.69e-05	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—HDAC2—hematologic cancer	3.05e-06	9.68e-05	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—CXCR4—hematologic cancer	3.05e-06	9.68e-05	CbGpPWpGaD
Adenosine—ADORA2A—Signaling by NGF—AKT1—hematologic cancer	3.05e-06	9.68e-05	CbGpPWpGaD
Adenosine—ADORA1—Signaling by GPCR—JAK2—hematologic cancer	3.04e-06	9.64e-05	CbGpPWpGaD
Adenosine—ADORA2B—Signaling Pathways—PDGFB—hematologic cancer	3.03e-06	9.61e-05	CbGpPWpGaD
Adenosine—ADORA1—Signaling Pathways—HES1—hematologic cancer	3.01e-06	9.56e-05	CbGpPWpGaD
Adenosine—ADORA1—Signaling Pathways—NCOR1—hematologic cancer	3e-06	9.5e-05	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—CBL—hematologic cancer	2.98e-06	9.43e-05	CbGpPWpGaD
Adenosine—ADA—Metabolism—PIK3R1—hematologic cancer	2.97e-06	9.42e-05	CbGpPWpGaD
Adenosine—ADORA2B—Signaling Pathways—TSC2—hematologic cancer	2.96e-06	9.39e-05	CbGpPWpGaD
Adenosine—ADORA1—Signaling Pathways—CSF2—hematologic cancer	2.96e-06	9.39e-05	CbGpPWpGaD
Adenosine—ADORA1—Signaling Pathways—FGF1—hematologic cancer	2.96e-06	9.39e-05	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—IL3—hematologic cancer	2.94e-06	9.33e-05	CbGpPWpGaD
Adenosine—ADORA1—Signaling Pathways—FOXO1—hematologic cancer	2.92e-06	9.26e-05	CbGpPWpGaD
Adenosine—ADORA1—GPCR downstream signaling—IL2—hematologic cancer	2.92e-06	9.25e-05	CbGpPWpGaD
Adenosine—ADORA1—Signaling Pathways—PDGFRB—hematologic cancer	2.92e-06	9.24e-05	CbGpPWpGaD
Adenosine—ADORA2A—Signaling by GPCR—PIK3CG—hematologic cancer	2.91e-06	9.22e-05	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—PTPN1—hematologic cancer	2.89e-06	9.18e-05	CbGpPWpGaD
Adenosine—ADORA1—Signaling by GPCR—PIK3CB—hematologic cancer	2.89e-06	9.15e-05	CbGpPWpGaD
Adenosine—ADORA1—Signaling Pathways—PDGFRA—hematologic cancer	2.87e-06	9.1e-05	CbGpPWpGaD
Adenosine—ADORA1—Signaling Pathways—JAK1—hematologic cancer	2.86e-06	9.07e-05	CbGpPWpGaD
Adenosine—ADORA1—Signaling Pathways—PRKCG—hematologic cancer	2.86e-06	9.07e-05	CbGpPWpGaD
Adenosine—ADORA2A—Signaling by GPCR—PTPN11—hematologic cancer	2.86e-06	9.06e-05	CbGpPWpGaD
Adenosine—ADORA2B—Signaling Pathways—FGFR3—hematologic cancer	2.85e-06	9.04e-05	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—RASGRP1—hematologic cancer	2.85e-06	9.03e-05	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—SYK—hematologic cancer	2.84e-06	9e-05	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—HSP90AA1—hematologic cancer	2.84e-06	9e-05	CbGpPWpGaD
Adenosine—ADORA2B—Signaling Pathways—MAPK14—hematologic cancer	2.82e-06	8.95e-05	CbGpPWpGaD
Adenosine—ADORA2A—GPCR downstream signaling—PIK3CD—hematologic cancer	2.82e-06	8.93e-05	CbGpPWpGaD
Adenosine—ADORA2B—Signaling Pathways—ESR1—hematologic cancer	2.77e-06	8.78e-05	CbGpPWpGaD
Adenosine—ADORA2A—Signaling by GPCR—CREB1—hematologic cancer	2.77e-06	8.78e-05	CbGpPWpGaD
Adenosine—ADA—Metabolism—PIK3CB—hematologic cancer	2.74e-06	8.69e-05	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—STAT1—hematologic cancer	2.74e-06	8.68e-05	CbGpPWpGaD
Adenosine—ADORA2B—Signaling Pathways—FN1—hematologic cancer	2.74e-06	8.67e-05	CbGpPWpGaD
Adenosine—ADORA2A—Signaling by GPCR—CCL2—hematologic cancer	2.71e-06	8.59e-05	CbGpPWpGaD
Adenosine—ADORA2B—Signaling Pathways—BAD—hematologic cancer	2.7e-06	8.57e-05	CbGpPWpGaD
Adenosine—ADORA2B—Signaling Pathways—NFKBIA—hematologic cancer	2.7e-06	8.57e-05	CbGpPWpGaD
Adenosine—ADORA2A—Signaling by GPCR—IL6R—hematologic cancer	2.7e-06	8.56e-05	CbGpPWpGaD
Adenosine—ADORA2B—Signaling Pathways—NOTCH1—hematologic cancer	2.68e-06	8.48e-05	CbGpPWpGaD
Adenosine—ADORA1—Signaling Pathways—IL2RA—hematologic cancer	2.67e-06	8.47e-05	CbGpPWpGaD
Adenosine—ADORA2A—GPCR downstream signaling—PIK3R1—hematologic cancer	2.66e-06	8.43e-05	CbGpPWpGaD
Adenosine—ADORA1—Signaling by GPCR—IL2—hematologic cancer	2.65e-06	8.4e-05	CbGpPWpGaD
Adenosine—ADORA1—Signaling Pathways—TERT—hematologic cancer	2.64e-06	8.37e-05	CbGpPWpGaD
Adenosine—ADORA2B—Signaling Pathways—CD80—hematologic cancer	2.62e-06	8.31e-05	CbGpPWpGaD
Adenosine—ADORA2B—Signaling Pathways—KIT—hematologic cancer	2.62e-06	8.3e-05	CbGpPWpGaD
Adenosine—ADORA2B—Signaling Pathways—PIK3CG—hematologic cancer	2.62e-06	8.3e-05	CbGpPWpGaD
Adenosine—ADORA2B—Signaling by GPCR—NRAS—hematologic cancer	2.62e-06	8.3e-05	CbGpPWpGaD
Adenosine—ADORA2A—GPCR downstream signaling—JAK2—hematologic cancer	2.58e-06	8.19e-05	CbGpPWpGaD
Adenosine—ADORA1—Signaling Pathways—PDGFB—hematologic cancer	2.58e-06	8.17e-05	CbGpPWpGaD
Adenosine—ADORA2A—Signaling by GPCR—MAP2K1—hematologic cancer	2.57e-06	8.16e-05	CbGpPWpGaD
Adenosine—ADORA2B—Signaling Pathways—PTPN11—hematologic cancer	2.57e-06	8.15e-05	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—GRB2—hematologic cancer	2.56e-06	8.12e-05	CbGpPWpGaD
Adenosine—ADORA2A—Signaling by GPCR—PIK3CD—hematologic cancer	2.56e-06	8.11e-05	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—PDGFA—hematologic cancer	2.55e-06	8.1e-05	CbGpPWpGaD
Adenosine—ADORA1—Signaling Pathways—TSC2—hematologic cancer	2.52e-06	7.99e-05	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—KITLG—hematologic cancer	2.52e-06	7.98e-05	CbGpPWpGaD
Adenosine—ADORA2B—Signaling by GPCR—MAPK3—hematologic cancer	2.51e-06	7.95e-05	CbGpPWpGaD
Adenosine—ADORA2B—Signaling Pathways—CREB1—hematologic cancer	2.49e-06	7.9e-05	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—STAT5A—hematologic cancer	2.46e-06	7.8e-05	CbGpPWpGaD
Adenosine—ADORA2B—Signaling Pathways—BRAF—hematologic cancer	2.46e-06	7.8e-05	CbGpPWpGaD
Adenosine—ADK—Metabolism—PIK3CA—hematologic cancer	2.46e-06	7.79e-05	CbGpPWpGaD
Adenosine—ADORA2A—GPCR downstream signaling—PIK3CB—hematologic cancer	2.45e-06	7.78e-05	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—CDKN2B—hematologic cancer	2.44e-06	7.73e-05	CbGpPWpGaD
Adenosine—ADORA2B—Signaling Pathways—CCL2—hematologic cancer	2.44e-06	7.73e-05	CbGpPWpGaD
Adenosine—ADORA2B—Signaling Pathways—IL6R—hematologic cancer	2.43e-06	7.7e-05	CbGpPWpGaD
Adenosine—ADORA2B—Signaling Pathways—CREBBP—hematologic cancer	2.43e-06	7.69e-05	CbGpPWpGaD
Adenosine—ADORA1—Signaling Pathways—FGFR3—hematologic cancer	2.42e-06	7.68e-05	CbGpPWpGaD
Adenosine—ADORA2A—Signaling by GPCR—PIK3R1—hematologic cancer	2.41e-06	7.65e-05	CbGpPWpGaD
Adenosine—ADORA1—Signaling Pathways—MAPK14—hematologic cancer	2.4e-06	7.61e-05	CbGpPWpGaD
Adenosine—ADA—Metabolism—PTEN—hematologic cancer	2.37e-06	7.51e-05	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—CD86—hematologic cancer	2.36e-06	7.48e-05	CbGpPWpGaD
Adenosine—ADORA1—Signaling Pathways—ESR1—hematologic cancer	2.35e-06	7.46e-05	CbGpPWpGaD
Adenosine—ADORA2A—Signaling by GPCR—JAK2—hematologic cancer	2.35e-06	7.44e-05	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—HES1—hematologic cancer	2.33e-06	7.38e-05	CbGpPWpGaD
Adenosine—ADORA1—Signaling Pathways—FN1—hematologic cancer	2.33e-06	7.37e-05	CbGpPWpGaD
Adenosine—ADORA2B—Signaling Pathways—MAP2K1—hematologic cancer	2.32e-06	7.34e-05	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—NCOR1—hematologic cancer	2.31e-06	7.34e-05	CbGpPWpGaD
Adenosine—ADORA2B—Signaling Pathways—PIK3CD—hematologic cancer	2.3e-06	7.29e-05	CbGpPWpGaD
Adenosine—ADORA1—Signaling Pathways—BAD—hematologic cancer	2.3e-06	7.28e-05	CbGpPWpGaD
Adenosine—ADORA1—Signaling Pathways—NFKBIA—hematologic cancer	2.3e-06	7.28e-05	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—CSF2—hematologic cancer	2.29e-06	7.25e-05	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—FGF1—hematologic cancer	2.29e-06	7.25e-05	CbGpPWpGaD
Adenosine—ADORA2B—GPCR downstream signaling—PIK3CA—hematologic cancer	2.28e-06	7.22e-05	CbGpPWpGaD
Adenosine—ADORA1—Signaling Pathways—NOTCH1—hematologic cancer	2.28e-06	7.21e-05	CbGpPWpGaD
Adenosine—ADA—Metabolism—EP300—hematologic cancer	2.26e-06	7.16e-05	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—FOXO1—hematologic cancer	2.26e-06	7.15e-05	CbGpPWpGaD
Adenosine—ADORA2A—GPCR downstream signaling—IL2—hematologic cancer	2.25e-06	7.15e-05	CbGpPWpGaD
Adenosine—ADORA2B—Signaling by GPCR—KRAS—hematologic cancer	2.25e-06	7.14e-05	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—PDGFRB—hematologic cancer	2.25e-06	7.14e-05	CbGpPWpGaD
Adenosine—ADORA1—Signaling Pathways—CD80—hematologic cancer	2.23e-06	7.07e-05	CbGpPWpGaD
Adenosine—ADORA2A—Signaling by GPCR—PIK3CB—hematologic cancer	2.23e-06	7.07e-05	CbGpPWpGaD
Adenosine—ADORA1—Signaling Pathways—PIK3CG—hematologic cancer	2.23e-06	7.06e-05	CbGpPWpGaD
Adenosine—ADORA1—Signaling Pathways—KIT—hematologic cancer	2.23e-06	7.06e-05	CbGpPWpGaD
Adenosine—ADORA1—Signaling by GPCR—NRAS—hematologic cancer	2.23e-06	7.05e-05	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—PDGFRA—hematologic cancer	2.22e-06	7.03e-05	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—PRKCG—hematologic cancer	2.21e-06	7e-05	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—JAK1—hematologic cancer	2.21e-06	7e-05	CbGpPWpGaD
Adenosine—ADORA2B—Signaling Pathways—FGF2—hematologic cancer	2.2e-06	6.98e-05	CbGpPWpGaD
Adenosine—ADORA1—Signaling Pathways—PTPN11—hematologic cancer	2.19e-06	6.93e-05	CbGpPWpGaD
Adenosine—ADORA2B—Signaling Pathways—PIK3R1—hematologic cancer	2.17e-06	6.89e-05	CbGpPWpGaD
Adenosine—ADORA1—Signaling by GPCR—MAPK3—hematologic cancer	2.13e-06	6.76e-05	CbGpPWpGaD
Adenosine—ADORA1—Signaling Pathways—CREB1—hematologic cancer	2.12e-06	6.72e-05	CbGpPWpGaD
Adenosine—ADORA2B—Signaling Pathways—JAK2—hematologic cancer	2.11e-06	6.69e-05	CbGpPWpGaD
Adenosine—ADORA1—Signaling Pathways—BRAF—hematologic cancer	2.09e-06	6.63e-05	CbGpPWpGaD
Adenosine—ADORA1—Signaling Pathways—CCL2—hematologic cancer	2.07e-06	6.57e-05	CbGpPWpGaD
Adenosine—ADORA2B—Signaling by GPCR—PIK3CA—hematologic cancer	2.07e-06	6.56e-05	CbGpPWpGaD
Adenosine—ADORA1—Signaling Pathways—IL6R—hematologic cancer	2.07e-06	6.55e-05	CbGpPWpGaD
Adenosine—ADORA1—Signaling Pathways—CREBBP—hematologic cancer	2.06e-06	6.54e-05	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—IL2RA—hematologic cancer	2.06e-06	6.54e-05	CbGpPWpGaD
Adenosine—ADORA2B—Signaling Pathways—MDM2—hematologic cancer	2.06e-06	6.53e-05	CbGpPWpGaD
Adenosine—ADORA2A—Signaling by GPCR—IL2—hematologic cancer	2.05e-06	6.49e-05	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—TERT—hematologic cancer	2.04e-06	6.47e-05	CbGpPWpGaD
Adenosine—ADK—Metabolism—AKT1—hematologic cancer	2.01e-06	6.37e-05	CbGpPWpGaD
Adenosine—ADORA2B—Signaling Pathways—PIK3CB—hematologic cancer	2.01e-06	6.36e-05	CbGpPWpGaD
Adenosine—ADORA2B—Signaling Pathways—MTOR—hematologic cancer	2.01e-06	6.36e-05	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—PDGFB—hematologic cancer	1.99e-06	6.31e-05	CbGpPWpGaD
Adenosine—ADORA1—Signaling Pathways—MAP2K1—hematologic cancer	1.97e-06	6.24e-05	CbGpPWpGaD
Adenosine—ADORA1—Signaling Pathways—PIK3CD—hematologic cancer	1.96e-06	6.2e-05	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—TSC2—hematologic cancer	1.95e-06	6.17e-05	CbGpPWpGaD
Adenosine—ADORA1—GPCR downstream signaling—PIK3CA—hematologic cancer	1.94e-06	6.14e-05	CbGpPWpGaD
Adenosine—ADORA1—Signaling by GPCR—KRAS—hematologic cancer	1.92e-06	6.07e-05	CbGpPWpGaD
Adenosine—ADORA2B—Signaling by GPCR—HRAS—hematologic cancer	1.91e-06	6.07e-05	CbGpPWpGaD
Adenosine—ADORA2B—Signaling Pathways—CDKN1B—hematologic cancer	1.88e-06	5.97e-05	CbGpPWpGaD
Adenosine—ADORA1—Signaling Pathways—FGF2—hematologic cancer	1.87e-06	5.94e-05	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—FGFR3—hematologic cancer	1.87e-06	5.93e-05	CbGpPWpGaD
Adenosine—ADORA2B—GPCR downstream signaling—AKT1—hematologic cancer	1.86e-06	5.9e-05	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—MAPK14—hematologic cancer	1.85e-06	5.87e-05	CbGpPWpGaD
Adenosine—ADORA1—Signaling Pathways—PIK3R1—hematologic cancer	1.85e-06	5.86e-05	CbGpPWpGaD
Adenosine—ADORA2B—Signaling Pathways—CASP3—hematologic cancer	1.84e-06	5.85e-05	CbGpPWpGaD
Adenosine—ADORA2B—Signaling Pathways—IL2—hematologic cancer	1.84e-06	5.84e-05	CbGpPWpGaD
Adenosine—ADORA2B—Signaling by GPCR—IL6—hematologic cancer	1.83e-06	5.81e-05	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—ESR1—hematologic cancer	1.82e-06	5.76e-05	CbGpPWpGaD
Adenosine—ADORA2B—Signaling Pathways—CCND1—hematologic cancer	1.8e-06	5.69e-05	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—FN1—hematologic cancer	1.8e-06	5.69e-05	CbGpPWpGaD
Adenosine—ADORA1—Signaling Pathways—JAK2—hematologic cancer	1.8e-06	5.69e-05	CbGpPWpGaD
Adenosine—ADORA2B—Signaling Pathways—JUN—hematologic cancer	1.79e-06	5.68e-05	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—BAD—hematologic cancer	1.77e-06	5.62e-05	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—NFKBIA—hematologic cancer	1.77e-06	5.62e-05	CbGpPWpGaD
Adenosine—ADORA1—Signaling by GPCR—PIK3CA—hematologic cancer	1.76e-06	5.58e-05	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—NOTCH1—hematologic cancer	1.76e-06	5.57e-05	CbGpPWpGaD
Adenosine—ADORA1—Signaling Pathways—MDM2—hematologic cancer	1.75e-06	5.56e-05	CbGpPWpGaD
Adenosine—ADORA2B—Signaling Pathways—CDKN1A—hematologic cancer	1.74e-06	5.51e-05	CbGpPWpGaD
Adenosine—ADORA2B—Signaling Pathways—PTEN—hematologic cancer	1.73e-06	5.49e-05	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—CD80—hematologic cancer	1.72e-06	5.46e-05	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—KIT—hematologic cancer	1.72e-06	5.45e-05	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—PIK3CG—hematologic cancer	1.72e-06	5.45e-05	CbGpPWpGaD
Adenosine—ADORA2A—Signaling by GPCR—NRAS—hematologic cancer	1.72e-06	5.45e-05	CbGpPWpGaD
Adenosine—ADORA1—Signaling Pathways—PIK3CB—hematologic cancer	1.71e-06	5.41e-05	CbGpPWpGaD
Adenosine—ADORA1—Signaling Pathways—MTOR—hematologic cancer	1.71e-06	5.41e-05	CbGpPWpGaD
Adenosine—ADORA2B—Signaling Pathways—MAPK8—hematologic cancer	1.7e-06	5.37e-05	CbGpPWpGaD
Adenosine—ADORA2B—Signaling by GPCR—AKT1—hematologic cancer	1.69e-06	5.36e-05	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—PTPN11—hematologic cancer	1.69e-06	5.35e-05	CbGpPWpGaD
Adenosine—ADA—Metabolism—PIK3CA—hematologic cancer	1.67e-06	5.3e-05	CbGpPWpGaD
Adenosine—ADORA2B—Signaling Pathways—EP300—hematologic cancer	1.65e-06	5.24e-05	CbGpPWpGaD
Adenosine—ADORA2A—Signaling by GPCR—MAPK3—hematologic cancer	1.65e-06	5.22e-05	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—CREB1—hematologic cancer	1.64e-06	5.18e-05	CbGpPWpGaD
Adenosine—ADORA1—Signaling by GPCR—HRAS—hematologic cancer	1.63e-06	5.16e-05	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—BRAF—hematologic cancer	1.62e-06	5.12e-05	CbGpPWpGaD
Adenosine—ADORA2B—Signaling Pathways—SRC—hematologic cancer	1.61e-06	5.09e-05	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—CCL2—hematologic cancer	1.6e-06	5.07e-05	CbGpPWpGaD
Adenosine—ADORA1—Signaling Pathways—CDKN1B—hematologic cancer	1.6e-06	5.07e-05	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—IL6R—hematologic cancer	1.6e-06	5.06e-05	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—CREBBP—hematologic cancer	1.59e-06	5.05e-05	CbGpPWpGaD
Adenosine—ADORA1—GPCR downstream signaling—AKT1—hematologic cancer	1.58e-06	5.02e-05	CbGpPWpGaD
Adenosine—ADORA1—Signaling Pathways—CASP3—hematologic cancer	1.57e-06	4.97e-05	CbGpPWpGaD
Adenosine—ADORA1—Signaling Pathways—IL2—hematologic cancer	1.57e-06	4.96e-05	CbGpPWpGaD
Adenosine—ADORA2B—Signaling Pathways—VEGFA—hematologic cancer	1.57e-06	4.96e-05	CbGpPWpGaD
Adenosine—ADORA1—Signaling by GPCR—IL6—hematologic cancer	1.56e-06	4.94e-05	CbGpPWpGaD
Adenosine—ADORA2B—Signaling Pathways—STAT3—hematologic cancer	1.55e-06	4.91e-05	CbGpPWpGaD
Adenosine—ADORA2B—Signaling Pathways—NRAS—hematologic cancer	1.55e-06	4.9e-05	CbGpPWpGaD
Adenosine—ADORA1—Signaling Pathways—CCND1—hematologic cancer	1.53e-06	4.84e-05	CbGpPWpGaD
Adenosine—ADORA1—Signaling Pathways—JUN—hematologic cancer	1.52e-06	4.83e-05	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—MAP2K1—hematologic cancer	1.52e-06	4.82e-05	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—PIK3CD—hematologic cancer	1.51e-06	4.79e-05	CbGpPWpGaD
Adenosine—ADORA2A—GPCR downstream signaling—PIK3CA—hematologic cancer	1.5e-06	4.74e-05	CbGpPWpGaD
Adenosine—ADORA2B—Signaling Pathways—MAPK3—hematologic cancer	1.48e-06	4.69e-05	CbGpPWpGaD
Adenosine—ADORA2A—Signaling by GPCR—KRAS—hematologic cancer	1.48e-06	4.69e-05	CbGpPWpGaD
Adenosine—ADORA1—Signaling Pathways—CDKN1A—hematologic cancer	1.48e-06	4.68e-05	CbGpPWpGaD
Adenosine—ADORA1—Signaling Pathways—PTEN—hematologic cancer	1.47e-06	4.67e-05	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—FGF2—hematologic cancer	1.45e-06	4.58e-05	CbGpPWpGaD
Adenosine—ADORA1—Signaling Pathways—MAPK8—hematologic cancer	1.44e-06	4.57e-05	CbGpPWpGaD
Adenosine—ADORA2B—Signaling Pathways—MYC—hematologic cancer	1.44e-06	4.57e-05	CbGpPWpGaD
Adenosine—ADORA1—Signaling by GPCR—AKT1—hematologic cancer	1.44e-06	4.56e-05	CbGpPWpGaD
Adenosine—ADORA2B—Signaling Pathways—TGFB1—hematologic cancer	1.44e-06	4.55e-05	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—PIK3R1—hematologic cancer	1.43e-06	4.52e-05	CbGpPWpGaD
Adenosine—ADORA1—Signaling Pathways—EP300—hematologic cancer	1.41e-06	4.45e-05	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—JAK2—hematologic cancer	1.39e-06	4.39e-05	CbGpPWpGaD
Adenosine—ADORA1—Signaling Pathways—SRC—hematologic cancer	1.37e-06	4.33e-05	CbGpPWpGaD
Adenosine—ADA—Metabolism—AKT1—hematologic cancer	1.37e-06	4.33e-05	CbGpPWpGaD
Adenosine—ADORA2A—Signaling by GPCR—PIK3CA—hematologic cancer	1.36e-06	4.31e-05	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—MDM2—hematologic cancer	1.35e-06	4.29e-05	CbGpPWpGaD
Adenosine—ADORA1—Signaling Pathways—VEGFA—hematologic cancer	1.33e-06	4.22e-05	CbGpPWpGaD
Adenosine—ADORA2B—Signaling Pathways—KRAS—hematologic cancer	1.33e-06	4.22e-05	CbGpPWpGaD
Adenosine—ADORA1—Signaling Pathways—STAT3—hematologic cancer	1.32e-06	4.18e-05	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—MTOR—hematologic cancer	1.32e-06	4.17e-05	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—PIK3CB—hematologic cancer	1.32e-06	4.17e-05	CbGpPWpGaD
Adenosine—ADORA1—Signaling Pathways—NRAS—hematologic cancer	1.31e-06	4.17e-05	CbGpPWpGaD
Adenosine—ADORA1—Signaling Pathways—MAPK3—hematologic cancer	1.26e-06	3.99e-05	CbGpPWpGaD
Adenosine—ADORA2A—Signaling by GPCR—HRAS—hematologic cancer	1.26e-06	3.98e-05	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—CDKN1B—hematologic cancer	1.24e-06	3.92e-05	CbGpPWpGaD
Adenosine—ADORA1—Signaling Pathways—MYC—hematologic cancer	1.22e-06	3.88e-05	CbGpPWpGaD
Adenosine—ADORA2B—Signaling Pathways—PIK3CA—hematologic cancer	1.22e-06	3.88e-05	CbGpPWpGaD
Adenosine—ADORA2A—GPCR downstream signaling—AKT1—hematologic cancer	1.22e-06	3.87e-05	CbGpPWpGaD
Adenosine—ADORA1—Signaling Pathways—TGFB1—hematologic cancer	1.22e-06	3.87e-05	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—CASP3—hematologic cancer	1.21e-06	3.84e-05	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—IL2—hematologic cancer	1.21e-06	3.83e-05	CbGpPWpGaD
Adenosine—ADORA2A—Signaling by GPCR—IL6—hematologic cancer	1.2e-06	3.81e-05	CbGpPWpGaD
Adenosine—ADORA2B—Signaling Pathways—TP53—hematologic cancer	1.18e-06	3.75e-05	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—CCND1—hematologic cancer	1.18e-06	3.74e-05	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—JUN—hematologic cancer	1.18e-06	3.73e-05	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—CDKN1A—hematologic cancer	1.14e-06	3.61e-05	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—PTEN—hematologic cancer	1.14e-06	3.61e-05	CbGpPWpGaD
Adenosine—ADORA1—Signaling Pathways—KRAS—hematologic cancer	1.13e-06	3.59e-05	CbGpPWpGaD
Adenosine—ADORA2B—Signaling Pathways—HRAS—hematologic cancer	1.13e-06	3.59e-05	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—MAPK8—hematologic cancer	1.11e-06	3.53e-05	CbGpPWpGaD
Adenosine—ADORA2A—Signaling by GPCR—AKT1—hematologic cancer	1.11e-06	3.52e-05	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—EP300—hematologic cancer	1.09e-06	3.44e-05	CbGpPWpGaD
Adenosine—ADORA2B—Signaling Pathways—IL6—hematologic cancer	1.08e-06	3.43e-05	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—SRC—hematologic cancer	1.06e-06	3.34e-05	CbGpPWpGaD
Adenosine—ADORA1—Signaling Pathways—PIK3CA—hematologic cancer	1.04e-06	3.3e-05	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—VEGFA—hematologic cancer	1.03e-06	3.26e-05	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—STAT3—hematologic cancer	1.02e-06	3.23e-05	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—NRAS—hematologic cancer	1.02e-06	3.22e-05	CbGpPWpGaD
Adenosine—ADORA1—Signaling Pathways—TP53—hematologic cancer	1.01e-06	3.19e-05	CbGpPWpGaD
Adenosine—ADORA2B—Signaling Pathways—AKT1—hematologic cancer	9.99e-07	3.17e-05	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—MAPK3—hematologic cancer	9.72e-07	3.08e-05	CbGpPWpGaD
Adenosine—ADORA1—Signaling Pathways—HRAS—hematologic cancer	9.62e-07	3.05e-05	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—MYC—hematologic cancer	9.46e-07	3e-05	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—TGFB1—hematologic cancer	9.43e-07	2.99e-05	CbGpPWpGaD
Adenosine—ADORA1—Signaling Pathways—IL6—hematologic cancer	9.21e-07	2.92e-05	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—KRAS—hematologic cancer	8.74e-07	2.77e-05	CbGpPWpGaD
Adenosine—ADORA1—Signaling Pathways—AKT1—hematologic cancer	8.49e-07	2.69e-05	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—PIK3CA—hematologic cancer	8.03e-07	2.54e-05	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—TP53—hematologic cancer	7.76e-07	2.46e-05	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—HRAS—hematologic cancer	7.43e-07	2.35e-05	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—IL6—hematologic cancer	7.11e-07	2.25e-05	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—AKT1—hematologic cancer	6.56e-07	2.08e-05	CbGpPWpGaD
